Genomics services across the drug development lifecycle
Our genomics services team can work with you to select the most effective platforms and assays to address your drug development objectives. Whether you need targeted or comprehensive capabilities in preclinical or clinical trials, we can help you better understand the biology of disease from biomarker discovery through to commercialization.
Harness the power of biomarker and CDx strategies for clinical trial success
The use of biomarkers in clinical drug development programs is a growing requirement for many disease areas that have shifted from the one-drug-for-all to targeted therapy trials. Like never before biopharmaceutical companies are incorporating the use of biomarkers in diagnosing, monitoring and treating some of today’s most complex diseases. Having a comprehensive biomarker strategy can be crucial to ensuring clinical and commercial success of your product.
Solutions has helped develop some of the industry’s most well-known biomarkers for personalized medicine, we have the expertise to develop a fit-for-purpose biomarker discovery and development strategy based on scientific knowledge and development experience, mitigating risks for improved clinical outcomes.
The growing trend in drug development towards personalized medicine necessitates co-development of the diagnostic with the targeted therapy to deliver the right treatment at the right time and the right dose to the right patient. With Q2
Solutions’ comprehensive solution for companion diagnostic development, we can take your therapeutic in tandem with the companion diagnostic to market faster.
Uncover the relationships between genes, mutations and disease
Genomic data can be used to derive a deeper understanding of a compound’s biology. A mix of broad and targeted approaches lets you understand the big picture from identifying new pathways, to better predicting safety. Q2
Solutions | EA Genomics offers comprehensive DNA and RNA services through our CLIA certified lab. Our bioinformatics services are available for all listed assays to turn data into genomic insights.
- Custom cancer panels
- Epigenetic analysis
- Exome/targeted sequencing
- Human Leukocyte Antigen (HLA) allele calling
- Next generation sequencing
- Whole genome SNP profiling
- Targeting SNP profiling
- PacBio Single Molecule, Real-Time (SMRT symbol) DNA sequencing
- Sanger sequencing
- Target enrichment
- Total RNA-Seq
- FFPE RNA-Seq
- Fusion detection